Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

NCT02865434 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid

Interventions

DRUG: Tc99m-tilmanocept
PROCEDURE: SPECT Imaging (60 Minutes post-injection)
PROCEDURE: SPECT Imaging (180 Minutes post-injection)
PROCEDURE: Whole body planar SPECT imaging (15 Minutes post-injection)
PROCEDURE: Whole body planar SPECT imaging (60 Minutes post-injection)
PROCEDURE: Whole body planar SPECT imaging (180 Minutes post-injection)
PROCEDURE: Whole body planar SPECT imaging (18-20 Hours post-injection)
PROCEDURE: Blood Collection for PK Testing (15 Mins Before Injection)
PROCEDURE: Blood Collection for PK Testing (after injection)
PROCEDURE: Blood Collection for PK Testing (15 minutes post injection)
PROCEDURE: Blood Collection for PK Testing (60 minutes post injection)
PROCEDURE: Blood Collection for PK Testing (180 minutes post injection)
PROCEDURE: Blood Collection for PK Testing (18-20 hours post injection)
PROCEDURE: Planar Image with both Hands in Field of View

Sponsor

Navidea Biopharmaceuticals